Document GmXg0zjRR0QqMxGwE99Mq3md4
Northwest Bioanalytical
ARQAG -- 113 SStuudyeNo. mNWBsS0e0-1s45
Quantitative Determination of PFOS and Related Compounds in Human Serum by LC/MS/MS
Sample Analysis Report for Protocol
EPI-0016
Northwest Bioanalytical (NWB) A1D1i2v1iEsaisont o3f9N00WSTouItnhc.
Salt Lake City,UT84124
)
PREPARED FOR:
3M Company Corporate Occupational Medicine, Medical Department 220.3W-05 St. Paul, MN 55144
= =5 BS=E
Zz 5
=
8
AUTHOR: Lonwee Zedl7" Connie O. Sakashitz, B.S, NWB Project Manager APPROVED FOR SE BY:
fger L. Foltz, Ph.D., NWB Technical Director )
Page 1
DATE: /-/0- 02.
DATE: _/=/0-0
CONTA NO CRI
000599
Northwest Bioanalytical
RSetpuordty NNoo.. NNWWBBRSOO0I--114555
LABORATORY: SPONSOR:
QUALITY ASSURANCE STATEMENT
Northwest A Division
Bioanalytical ofNWT Inc.
(NWB)
S1a1l2t1LaEaksetC3i9ty0,0USTout8h4124
C3oMrpCooramtpeaOncycupational Medicine, Medical Department 220-3W-05 St. Paul, MN 55144.
COMPOUND(S):
PFOS and Related Compounds
NWB STUDY NUMBER:
NWBS00-145
SPONSOR STUDY NUMBER:~~ EPI-0016
NWB STUDY TITLE:
QCuoamnptiotuantidvse iDneHteurmmainnatSieornuomfbPyFLOOSMaSn/dMRSe,lated
J
r`Tehgeulcaltiendicnalonsctluidnyicdaelssctruidbye.d iHnotwheivserre,poNrotritshnwoetsitnBcilouadneadlywtiitchailnctohnedduecftisniatlilosntoudfiaesGwLiPthin the guidelines ofthe U.S. FDA Good Laboratory Practice Regulations for Nonclinical Laboratory
JStaupdaineesse(TMitHleW21GCoFoRd LPaarbtor5a8t),ortyhePrOaEctCicDe SPrtianncdiaprldesOrofdiGnoaondceLafobrorNaotnocrliynPircaacltiLcaeboarnadtothre.y
iSntsupdeicetsioonnstwheerSeafpeetryfoofrmDerdugbsy(tOherdNinWaBnceQNAo.U 2p1e,rPSOAPB.Notification No. 424.) The following
Inspection and Reporting Statement.
DateofInspection ~~ PhoafSstuedy
22:23 0ct 2001 2224:O2c3t02c0t021001 15-16 Nov 2001 07-09 Jan 2002 10 Jan 2002
Standards Preparation AQnCalyPtriecpaalraPtliaonn Sample Analysis FRienpaolrtReDproarftURaw Data
Date Report Sent to NWPProjectManager 230ct 2001 2234 0Occtt22000011 16 Nov 2001 09 Jan 2002 10 Jan 2002
Date Report Sent to NWBManagement*
31 0c2001
331100cett 22000011
30 Nov 2001 31 Jan 2002
~
31 Jan 2002
"Reports to NWB Management are issued monthly.
As can reasonably be incorporated into this
established, final report
atchceurmaettehloydrsefalnecdt
ptrhoecreaduwrdeastad.escribed
and
the
results
)
cy Lfin Chain, B.A.
NWB Quality Assurance Compliance Auditor
Date 01-10-02
000600
Page2
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSOOL0--115455
COMPLIANCE STATEMENT
"rTehgeulcaltiendicanlonsctluidnyicdaelssctruidbye.d iHnowtehiverre,potrot tihsenobtesitnocflouuderdkwniotwhliendtghee,dtehfiisniptrioojnecotfawaGsLP cReognudluacttieodnsinfaorccNoorndcalninciecwailtLhatbhoeragtuiodreylSitneusdioefts h(TeitUl.eS.21FCDFARGPoarotd5L8a)baonrdataocrcyoPrrdaicntgicteo ttMhheeHmgWueitdGheoolodinsdeasLnaodbfoptrrhaoetcoOerdEyuPCrreaDsctPdireciesnccSriitpbalenedsdaworiftdGhiOonroddtihniLsaanrbecoperoarftto.orrNyIonnPrcaadlcdiitntiiiccoeanla,nLtdahbetohsretauJtdaoyprayfnoSeltslueodwieeds oiinnnccitldhueedneStdasfitenhtatythoimsfarDyerpohuragtvs.e(TaOhfrifdseicnrteaepndoctretheNroeq.pura2el1si,etnyPtosAraBinnNtaoectgciruifrtiaycotafettirohenecoNrpodr.ooj4fe2c4tth.oe) rAarnewpyodarkttnae.odwdnata is
[CoonnniecOe. SaOkashitfs, Bl.Soats NWB Project Manager ) ReffaerTeLc_hFnoilciazl, DPihr.eDc.tor
D/a-e10-02 -- /=1o--03
Date
000601 Puge3
Northwest Bioanalytical
TABLE OF CONTENTS
RSeptourdtyNNoo.. NNWWBBRSO0I0.-115455
SIGNATURE PAGE...
QUALITY ASSURANCE STATEMENT ccs
COMPLIANCE STATEMENT ccs
d
TABLE OF CONTENTS rns
LIST OF TABLES oss
LIST OF FIGURES...
1. INTRODUCTION.
2. METHODOLOGY conn)
3. SAMPLE ANALYSIS ccc
12
) 4 RESULTS AND DISCUSSION wo
|3
5. REFERENCES ovis
14
6. DATA RETENTION consists13
LIST OF TABLES
Table 1. Calibration Curve Summary for PROS...
16
Table 2. Calibration Curve SUMmMAry for PFOA ccs 1
Table 3. Calibration Curve Summary for PHS...
18
Table 4. Calibration Curve Summary fr PROSAA csr
19
Table 5. Calibration Curve Summary for PROSA ......rrrmsssssns20
Table 6. Calibration Curve SUMMArY fOr MSS6.......cvmmssissnssnn2]
Table 7. Calibration Curve SUMMATY for M570...
22.
) Table. Back-Calculated ConcentrationsofCalibration Standards for PFOS
nnn 23
000602
Pages
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSO0I0--115455
Table 9. Back-Caleulated Concentrations of Calibration Standards for PFOA ...............24
Table 10. Back-Calculated ConcentorfaCatliibroatniosn Standards for PFHS ..................25
Table 11. Back-Calculated ConcentrationsofCalibration Standards for PEOSAA................26
`Table 12. Back-Calculated ConcentrationsofCalibration Standards for PFOSA..........27
Table 13. Back-Calculated Concentrationsof Calibration Standards for MSS6 ...................28
Table 14. Back-Calculated ConcentrationsofCalibration Standards for M570 ...................29
`Table 15. Analytical QC SUMMATY fOr PROS...
30
Table 16. Analytical QC Summaryfor PFOA o.com 31
Table 17. Analytical QC SUMMATY f0 PFHS ccc
32
`Table 18. Analytical QC Summary fr PROSAA rcs
33
Table 19. Analytical QC SUmmMAry fOr PPOSA .vrcorcssssssnssnsnnrsonnn34.
y Teble20. Analytical QC SUMMAY or MSS6.covsmsn 35
Table21. Analytical QC SUMMARY fOr MST0..ccvrcmssssssnsnrnesenn36
`Table 22. Serum Study Sample CONGENLTAONS. rcs 37
LIST OF FIGURES
Figure |. Representative Calibration Curve for PROS .....corunccrronsnsnmsnrmnnn 45
Figure 2. Representative Calibration Curve fOr PFOA...
dS
Figure 3. Representative Calibration Curve for PFHS ......ccccsrsmmmsnsd
Figure 4. Representative Calibration Curve for PROSAA cvs
Figure 5. Representative Calibration Curve for PROSA. cvs dT
Figure 6. Representative Calibration Curve fr M536 .....uncuscrccorrsnsssnn41
Figure7. Representative Calibration Curve fOr M570...
d8
J) Figure S. Human Plasma BIank for PFOS ...omreccssnssssssnsndd
000603
Pages
Northwest Bioanalytical
ReSptourdtyNNoo. NNWWBBRSO0I0--115455
Figure9. Human Plasma BIAnk fOr PFOA wc...
50
Figure 10. Human Plasma BIankforPHS...
1
Figure 11. Human Plasma Blank for PFOSAA weenie
52
Figure 12. Human Plasma BInk for PFOSA ccs
53
Figure 13. HumanPIasmaBIaK for MSG...
54
Figure 14. Human Plasma BIankfor M570...
sms SS.
Figure 15. Human Plasma Blank with Intemal Standard (QO) for PFOS ........cov.omron 56
Figure 16. Human Plasma Blank with Internal Standard (QC) for PFOA... ST
Figure 17. Human PlasmaBlank with Internal Standard (QO) for PFHS oon58.
Figure 18. Human Plasma Blank with Intermal Standard (QO) for PFOSAA.......ccrr 59
Figure 19. Human Plasma Blank with Internal Standard (QO) for PFOSA cc... 60
Figure 20. Human Plasma Blank with Internal Standard (QC0) for M56...
6]
' Figure 21. Human Plasma Blank with Intemal Standard (QO) for M570...
62.
Figure 22. Low Standard for PROS.
63
Figure 23. Low Standard for PROA corners sss
64
Figure 24. Low Standard fr PFHS.ccvvonssssssssossssmsmmsn6S
Figure 25. Low Standard for PROSAA vrsG6.
Figure 26. Low Standard for PFOSA .vvcrsmnssssssnsnsonsomsnn1
Figure 27. LOW StanfdOraM5r56d...
Figure 28. Low Standard for MST0.cnnsntssssssnsssssioens69
Figure 29. High StanfdoraPrFdOS.ccvurmamscssnsnsnsnsmsnssnn 10
Figure 30. High StafonrPFdOAav rdests
1
Figure 31. High Standard for PHS...
12
"Figure 32. High Standard for PEOSAA rer ssm--r8
Pages
000664
NorthwestBioanalytical
Study No. NWBS00-145
Report No. NWBROI-155
Figure33. High SIAdard fOr PFOSA crosses 74
Figure 34. High SUNard fOr MSS6..orsssseses oon 75
Figure35. High Standard 07MST0.crcrrvrcmsessssensosmsmsesseeesonos 76
)
000605
Page?
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSO0I0--115455
Quantitative Determination of PFOS and Related Compounds in Human Serum by LC/MS/MS
Sample Analysis Report for Protocol EPI-0016
1. INTRODUCTION
`This report summarizes the analytical results from the quantitation of POS, PFOA, PFHS, PFOSAA, PFOSA, M556, and MS70 in human serum samples for 3M Company (3M) in support of Protocol EPL-0016 [5.1]. The LC/MS/MS method for the analytes has a targeted calibration curve range of 1.00 to 500 ppb (except for M556 which has a LLOQ 0F2.50 ppb). The actual calibration curve range for each analyte varies based upon the persistent levelsofthe analyte in the matrix. For this study, the assay exhibited the following LLOQ and ULOQ values:
)
-- -_-- -- oAn-- walye te
ILlLOeQ 0 uUoLOQQ
PFOS
337 ppb
413 ppb
PFOA
1.44 ppb
481 ppb
:
PFHS
1.36 ppb
522 ppb
PFOSAA
1.50 ppb
501 ppb
PFOSA
1.00 ppb
500 ppb
Mss
2.50 ppb
500 ppb
--0 Ms70
101.0p0 ppbb = s50000pppbb
The sponsor was 3M Company (Corporate Occupational Medicine, Medical Department,
220-3W-05, St. Paul, MN 55144), and the Study Director was JeffreHy. Mandel, M.D.,
M.P.H. The Study Contact at 3M was Jean M. Burris. James K. Lundberg was the
technical contact at 3M. The following is a list of NWB supervisory personnel involved
in the completionofthis work: Connie O. Sakashita, B.S. (NWB Project Manager);
Patrick Bennett, M.S., M.B.A. (NWB Laboratory Director); Rodger L. Foltz, Ph.D.
(NWB Technical Director). Laboratory personnel involved in the completionofthis
000606
Pages
Northwest Bioanalytical
ReSptourdty NNoo.. NNWWBBRSO0L0--115455
study included Suzanne Newman, B.S. (NWB Research Scientist); Laura Struhs, B.S. (NWB Scientist) and Anna Akrami, B.S. (NWB Associate ResearchScientist).
NWB SOPs and guidelines were used in the conduct of this studyand were available to study personnel in electronic and/or hard copy formats.
Date Study Initiated: _23-Oct-2001 Date Analyses Completed: 16-Nov-2001
`The clinical study described in this report is not included within the definition ofa GLP
regulated nonclinical study. However, Northwest Bioanalytical conducts all studies
within the guidelinesofthe U.S. FDA Good Laboratory Practice Regulations for
Nonclinical Laboratory Studies (Title 21 CFR Part 58), the OECD Principles ofGood
Laboratory Practice and the Japanese MHW Good Laboratory Practice Standard
Ordinance for Nonclinical Laboratory Studies on the SafetyofDrugs (Ordinance No. 21,
PAB Notification No. 424). Any changes to or deviations from the original protocol
(Analytical Plan) were documented through approved protocol amendments or deviation
)
memos and are retained within the raw data.
2. METHODOLOGY
:
The assay used for this study is reported in Northwest Bioanalytical reports NWBROO108 [5.2] and NWBR00-122 [5.3]. Chinese human plasma was used for the calibration
curves and quality control samples. Serum sample results obtained using plasma curves
are discussed in NWBR00-122.
Samples for this study were received at NWB on the following date:
TT RReeecepipit DDaatee
MNeummbbeerrof Samples Received Storage Condition
_--
(e(xexecpepttdduuirignagnaanahlyssiisy)
_-- 23-Oct-2001 = 262
w-20c C
) 000607
Pages
Northwest Bioanalytical Reference Material
ReSptourdtyNNoo.. NNWWBBRSOOL0--115455
Analyte PROS
Lot Number Purity Expiration Date Source Storage Conditions 193 100% 31-Dec2010 3M Room temperature
PFOA
25 100% 31-Dec2010 3M Room temperature
PFHS SE036 100% 01-Jan-2010 3M
20C
PFOSAA PFOSA
617 538% 31-Dec2010 3M Room temperature 214 100% 31-Dec-2010 3M Room temperature
MSS6 NBII3047-8D 99.89% 31-Dec-2010 3M Room temperature
Ms70 11850626 99.75% 31-Dec-2010 3M Room temperature
T THPFOS 59909 90%me31-aT Decs-20l0 3M Room temperature
`The reference material purity for PFOS, PFOSA, PFHS, and PFOA was not available prior to the conductof this study. Therefore, the reference material purity was assumed to be 100%. ) 3M contracted with Centre Analytical Laboratories, Inc., in State College, Pennsylvania to determine the absolute concentrationofPFOS, PFOA, and PFHS in NWB stock solutions used to prepare the analytical standards and controls used for this studies. All amangements for purity determinations and the transfer ofNWA solutions to Centre. Analytical Laboratories, Inc., were performed by 3M. Based on Centre Analytical Laboratories" results, the concentrationsofplasma calibrator and quality control samples were corrected using the following factors:
Analyte
PFOS PFOA PFHS
Correction Factor 0.821 0.961 1.043
Eight or more calibration standards were prepared on the day of each run by adding
)
100 uLofblank Chinese human plasma and 400 uLof 50 mM ammonium acetate in
Page 10
000608
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSO0L0--115455
`water (unadjusted pH ~6.9) to 13 x 100 mm polypropylene tubes. After abrief vortex
mixing, 10.0 kLof the appropriate spiking solution was added. The final calibration
:
standard concentrations in human plasma for each analyte are listed below:
--AAnnaalbyttee
PFOS
CaClailibbrraattiioonnSSttaannddaarrddCCoonncceennttrraattiioonnss**
3.37,4.60, 10.8, 23.1, 43.6, 84.6, 208, 331 and 413 ppb
PFOA
1.44,2.88, 10.1, 24.5, 48.5, 97.1, 241, 385 and 481ppb
PFHS
1.36,2.92, 10.7, 26.4, 52.5, 104, 261, 417 and 522ppb
PFOSAA
1.50,3.00, 10.5, 25.5, 50.5, 101, 251, 401 and 501 ppb
PFOSA
1.00, 2.50, 10.0, 25.0, 50.0, 100, 250, 400 and 500 ppb
M556
2.50, 10.0, 25.0, 50.0, 100, 250, 400 and 500 ppb.
--1 +2 TheMt0 50 ar7ge0t c_ 0 alibr_ at, ion cur2 ve r1a.n0g05 e, i2s.51.00 0,0 1p0p.b0, ,(02550.001 ,p55p00.e00x0 ,,c1e1p00t000 ,M,S22S55600,,, wh44i00c00haha2 nansddaS5L005 L00pOpQppbbo0 f 2.50 , pp),
pEloacshmaanawleydt.e has diffrent inal curve ange based upon the persistent levelsofthe anal i the un,
In addition, blank human plasma samples, both with and without internal standard
(designataesd QC0s and Blanks, respectively), were assayed in each analytical run.
)
Analytical QCs were prepared in Chinese human plasma on November 5, 2001 and stored
-
ina -20 C freezer. For each run, analytical QC levels were. assayed in duplicate.
QC Concentrations (ppb)* 0
Analyte
Low.
Medium
High
PFOS
5.83
126
331
PFOA
4.32
144
384
PFHS
448
156
417
PFOSAA
4.50
151
401
PFOSA
4.00
150
400
M556
--MM570 0
4.00
440.000
150
400
s15o0
440000
c*oTncheenttraargteitonQsCbacsoendceunptroantitohnesperresis4t.e0n0tplpevbe,ls1o5f0tphebaannaldy4te00inphpbe. hEuamcahnapnlaalystmeahsaesddiffrent QC
The internal standard (THPFOS) was added to all serum samples (except Blanks) for a
final concentration of approximately 200 ppb.
000609 Page 11
Northwest Bioanalytical
ReSptourdty NNoo.. NNWWBBRSO0I0--14555
The analytical method consisted ofa liquid-liquid extraction procedure followed by `evaporation and reconstitutionofthe extract residue with 20 mM ammonium acetate in water: 20 mM ammonium acetate in methanol (30:70 v/v). The samples were analyzed by liquid chromatography/tandem mass spectrometry using an API 3000. The instrument was operated in the multiple reaction monitoring (MRM) mode under optimized conditions for PFOS, PFOA, PFHS, PFOSAA, PFOSA, M556 and M570 detectionofthe negative ions formed by turboionspray ionization.
3. SAMPLE ANALYSIS
PFOS, PFOA, PFHS, PFOSAA, PFOSA, M556, M570, and THPFOS chromatographic peaks were integrated using the MacQuan software (version 1.6) with a smooth factor of
one. Quantitation was based upon quadratic regression analysisofweighted (1/x%)
calibration curves using area ratio vs. concentration utilizing Watson DMLIMS software
(version 6.1.1.04). The samples were injected in a systematic order.
J
31. Acceptance Criteria
For an analytical run to be accepted, it must have met the acceptance criteria listed below which are consistent with regulatory and industry recommendations. Calibration Curve
Each run will include in duplicate calibration standards at six or more concentrations covering the lower to upper limit of quantitation. For all analytes except PFOSA and PFOSAA, at least three-fourthsofthe calibration standard's back-calculated
concentrations must be within 15% (+ 20% for LLOQ) of their individual target
concentrations. For PFOSA and PFOSAA, at least three-fourths of the calibration standards back-calculated concentrations must be within + 20% (+ 25% for LLOQ) oftheir individual target concentrations. A calibration standard will be considered an outlier ifitis greater than two times the acceptance criteria for that standard.
)
000610
Page 12
Northwest Biounalyical
Lower Limit of Quantitation
RepSoturdty NNoo..NNWWBBSR0O0I-115455
The back-calculated concentrations ofat least oneof the duplicate lowest points in the
calibration curve must be within 25% of the target concentration for PFOSA and.
PFOSAA to qualify as the LLOQ and within + 20%of the target concentration to qualifyas the LLOQ for all other analytes. Ifthis criterion is not met, the next level is
subjected to the same test and the LLOQ raisedaccordingly.
Quality Control Samples
Each analytical run will include low, medium and high QC samples in duplicate. The
`measured concentrations ofat least two-thirdsofall analytical QCs must be within
20%of their target concentrations(+ 25% for PFOSA and PFOSAA), and no two
QCs at the same concentration can be outside the limit. Ifstudy samples require
dilution, a dilution QC will be analyzed in triplicate for each dilution level (except for
PFOSA and PFOSAA which should not be diluted with control matrix). At least two
}
dilution QCs at each level must be within 20%ofts target concentrations in order
to accept diluted study samples at that level. The dilution QC acceptance is
independent of the undiluted analytical QCacceptance.
4. RESULTS AND DISCUSSION
Serum sample results obtained using plasma curves for PFOA, PFHS, PFOSAA, PFOSA, M556, and M570 did not meet NWB SOP requirements for validation. Results may vary
on average up to 26% from results obtained using human serum calibration curves at
some concentration levels for PFOA, PFHS, PFOSAA, M556, and M570. For PFOSA,
results may vary on average up to 43% from results obtained using human serum
calibration curves. These data are reported in Assay Revalidation AddendumReport NWBRO0-122 [5.3]. However, in order to obtain the lower limitof quantitation of less
than $ ppb required by the sponsor, it was necessary to use plasma calibration curves.
)
Percent theoretical and percent bias are separate calculations determined from the`mean.
Therefore, due to rounding, percent theoretical plus percent bias may not equal 100.0%.
Pages
000611
Northwest Bioanalytical
ReSptourdtyNNoo., NNWWBBSROODL--114555
Each accepted run met the acceptance criteria set fo the calibration curve points, for the
lower limitof quantitation (LLOQ) and for the analytical qualitycontrol (QC) samples.
"RIuDn PRResOulSt PFResOulAt PRResEuSlt FFROesSulAt A| Commem
Accepted Accepted Accepted Accepted
2 Accepted Accepted Accepted Accepted
3 Accepled Accepted Accepted Accepted
4 5
NA Accepted
NA Accepted
NA Accepted
NA Accepted
Runssabmploeprerpartatioen rdor
6 Accepied Accepted Accepted Accepted
7 Accepled Accepted Accepted Accepted
8 Accepied Accepted Accepted Accepted
NIA= notapplicale
RIuDn PRFeOsStA ReMssulst RMess7ul0t
Comments
U Accepted Accepted Accepted
)
2 Accepted Accepted Accepted
3 Accepied Accepted Accepted
4 5
NA Accepted
NA Accepted
NA Runaborted, sample preparateironr Accepted
6 Accepied Accepted Accepted
7 Accepted Accepted Accepted
8 Accepied Accepied Accepted
NA =notapplicable
Any known circumstances that may have affected the quality or integrityof the data are.
included in this report.
5. REFERENCES
5.1. 3M Company Protocol EPL-0016. "Identificationof Fluorochemicals in Serum from and Elderly Population in the Seattle, Washington Metropolitan Area."
Page 14
000612
Northwest Bioanalytical
RepSoturdtyNNoo.. NNWWBBRSO0I0--115455
52. C.Sakashita. "Quantitative Determinationof PFOS, PFOSA, PFOSAA, POAA, PFHS, M556 and M570 in Human Serum by LC/MS/MS." Assay Revalidation Report. NWB Study NWBS00-040. NWB Report NWBRO010-8. January 24, 2001
$3. C.Sakashita. "Quantitative Determinationof PFOS, PFOSA, PFOSAA, POAA, PFHS, M556 2nd M570 in Human Serum by LC/MS/MS." Assay Revalidation Addendum Report. NWB Study NWBS00-040. NWB Report NWBR00-122. November 20, 2001.
6. DATARETENTION
The raw data and final report for this study will be stored in the NWB Archives, 1121
East 3900 South, Salt Lake City, UT 84124 per regulations and contract agreement. After
submissionofthe final report to the Sponsor, remaining study samples will be stored
under required conditions until confirmation of Sample Disposition/Retum Authorization
is received from the Sponsor. 3M Company will be notified concerning final disposition
}
ofrecords at completionofcontract obligations.
Page 15
000613
a es
Table I. Calibration Curve Summary for PFOS Quadratic weighted 1/x'. All concentrationsareexpressed as ppb.
Run
A
c
LLOQ |[ULOQ
[[5i3oewrsts01|[e5 TToomoon[[oowwwss osoo m||oomaenes||55n5577|]s aa11|] [63a|sooomon [ous owoms omer|557|a1] [I so] ToCsowror[coomoews]seorns[EoEm || S e ATIeT [wwA e||
!
`A, B, and Care coefficients used to define the calibration curve.
000614
Table 2. Calibration Curve Summary for PFOA
wT Quadratic weighted
I/x%.
All
c concentrations are
expresseads
ppb,
Toa
oro
[N[[iosvorvaatetoo||n[6 55ovTToooowwaotounnotstr [[[oooovouoosras[[aoomsomsse|ooowmoeemrn|||rrreesavs | svvi1t]]| [[ii6soovvaattoess||57 JJoovoomon[Toorwna[a-omzoomrsee[|oomra ||reevs| oarr]] [esmn]] Jooomwoono[voonwsse oammoomrse[|o-omseorrs | |] ] C welR 1 C TTwo osy [owr [I ea T |] ]
000615
Table 3. Calibration Curve Summary for PFHS
`Quadratic weighted 1x All concentrations ar expressedasppb.
al II I PP [[[ie1eo%svoont|||33Toooomoomnrnf[Jooosmoossnoes[oamosamurse||a_asssmreosr ||v11s3365e||5||| [[r1s5woovvzzooto||7sooooonoosmoer [aomaasrees |oasssm||11556]55|| CSCisseoel]t mTToJowuoom[mo[fwooomws[ s osT oawra s]asvorum s ||o]|
000616
Table d. Calibration Curve. Summary for PFOSAA
aTe r Quadratic weighted 1x'. All c concentarrae texiproesnsesdas Tio ppb.
Tog
[issorz|oomommo]r [aousss fieso|rzm osomts
([vseoml] TJoowowwonr [oToomommes[[ aomeeo]oosom s|| | m] a , C rev] PoToo o[--o-- rr{oraws-- [r os--T |T |
i
000617
es Sy
Table 5. Calibration Curve Summary for PFOSA
Quadratic weighted 1/x". All concentrations are.expressed as ppb.
[osRNuonvaDaitoer| hR1uen [oweAn [cams omc |ows|L1L6O6Q| U5L0O7Q]
[[N[11oe5N%voevaraattsnoosr||]csooTmoomoonno |oooooomrorasTTToooomsnisa||oaosmsmre|||111600000
5s0o]] so]
[o(va1te6| 3T2ooowv0ore2[[00o0v10e16nTooaomvmeo|oos m|| 110e0005rs0o]]
[S[imsso] we
TTToaosvowwwooonrr[TowwooomirenrTo[omoomwrmmms[[[aaoamsms| ||||| ]
, CAFTTT----T ------T
Page 20
000618
SR
Rvetsnges
Table 6. Calibration Curve Summary for M556 Quadratic weighted 1/x'. All concentrations are. expressed as ppb.
A
c
R- LLOQ [ULOQ
[[i1o3r3i[|5sooosonmor||coommrsrees [i5ovator 5 osomor| some
ascmee|aosmmer || 223500]| 55005 ]
[i6%ovato |5 osowor|woviss[aonisesors |230 |si]
[vesmo]l oToowotior| coovnvee[[moommma[]aamss | || | C [rer] T TtCwoeT e| wieT aoem [Toso | T
Poget
000{1619
Table 7. Calibration Curve Summary for M570
= Quadratic weighted 1/x'. All : concentrations are `expressed as ppb. Toe oro [oreN+umbver| oom Towne| sonar|ase|i or] f[iioenoeovvaonrror||5eT|oovmoomesTTooourrsmn|onooorse||aagsesso|| s11o0o | 30010]] [[iivveerv3oir]0+|7 oooomtomJToomoanra|ovoomimrs||aassssme||"sa1o0||s5r01]] 7 I so ToCmTom Toemey0s oomA eers[Eoorn |] , CoJrT11s--1 -- 1
000620
=I Tee wo ww so Table 8.
Back-Calculated Concentrationsof Calibration Standards for PFOS Quadratic weighted 1/x'. All concentrations are. `expressed as ppb.
[CC oomamtaT [| 3Tse5aaee[lwwoearv[[|wuoooa[|aowoJT|asosv[owossn[|aanvTTooaear[|oonm]]|
[s[ si [5TooT rw[eTaloows[[iosx[[aooo seT|ooewirseT[[oonasses[w a|TTooonrr||o3sro]]]
[Ct[ ostsrmssaoI r[|e5TTeasoenr[[saoaom[f[iooonnnJ[oar[aaann[[oawsnsas||aamo|Tono|
aari|] a|
[[ irs1|7TTeo5e0n[saasont [Ttiooor4[[[oo1no[[soaiswzT[omoeasr[[aaonTnisonu
sarr| ao]
) [eC m1 TTasT erTfeoanfTT usef[oov[[wooreT[T oassT|aoT weTToaT nn|aar]]
[wesaoll [ol
TToaa[[[vuswaw[[uowwnT[wwooew[[a5or[[T5a0os[oooanTF[ooooo[ara]]]
[C oo lT ToaTwTooe [oaT[awrTTaao e 5Toart[aar]
000621
Table 9. Back-Caleulated ConcentrationsofCalibration Standards for PFOA
`Quadratic weighted 1/x". All concentrationsareexpressaeds ppb.
(TowRsonior| I {var seonl[oi[woas|r os|
Tis[om Jose [oo[mn[wor
a
aor[ne]|
[[v[ eoretim||5+1T i0u|aasmos|o oowmwoa[|omassei[[|osoo onruToousr as n oo7wn[|aonine]]]
[verti |5TTowvoar[[[wowiawrT[[oo5nm[[ovao5oaoT|oosoeerr[[oooevrre[[ao0mw|o0r[|aari]]]
[[v[ seoriaw[| 57T 1|vvsatr[|[aaos0wo[[|o ooormm[[2sa0ss7o||oows nsoo [T|owuos [a0o6e [[oosnsT|[ao]rr]]
C [[ SmI s Ton w [om[eoo m[T aaossoT[oaoarT[ooomsees [[Taaann[|| T9a[aor]n]]
[[ C sol Tv ei [TT ooww[e oaT smm[wvT ro1[[raon rr[[sT or[eoT wt |[aeT [[o|r]
C [[oewi l TTToeornf[[aasrel[[w ssaa[[owor[[oow ns[[awwalaTawrow l[[w55l[[aa5nr]]]
tt
000622
Table 10. Back-Calculated Concentrations of Calibration Standards for PFHS
ntt d a Quadratic weighted 1/x". All concentrations are. `expressed as ppb.
[[C oommnaenT s]5|TorlJJaeooon]|wu0a5[|w0s7[|voo[r[iomnn[|amnw [[wwaoe5r]]] [C C imoT ]5o T Joos[l e tor [wsaosrn [[ooe 5nr[|imomo a[[[aoomns T[oor anroor]]| [[[ eevveon]]e sT n w[[waonr[e uwaos[[Jmvwoeso|[soa rira[T[oamsrJ[aoawml T[ooen]]| [mC ori1 ]7T[eowfT[eoannJ[[wworen[[aamoosrT[[ooovroe[[omweno[[oawmw[oooono[o]e|] DC [eI van]+TraT e[e50TTwvoT sTJT e20e7 foovs[Tior me[|aaow[aaaor]| [ [wsea]l Toe us [TTasownos[[eooween[[|a or5ass [[Joaionre[[aonae[[r wsso[[asor aose|| Cead l T Tworl[waeo r lowsJlower [liwol[awvlaurl[oaalawr]]
000623
Table 11. Back-QuCaadlractuilcawteeidghCeodnc1ex.ntrAlaltcioonncsentorfatCiaolniabrreaetxiproenssSetdaandpaprb.ds for PEOSAA
CEevsoEio R[tEoJEw|Ros[Ewn{Eov|R[Roe|E|E]
[C C ovomoT T[3T1wwaoiTlaeew[[[ooosos[[ao3o0rss[[[ow1tro [ownroros|Taoeoo
oaow|Tora]] a [oi]
[Csivssooritoor[[55 |ivaaeorJJasaornmo[[[arnsoasm[[|o0v0o6[|[ooonosrnJoimioo[[[aoerms[oaess|||rr]|]
[tC CwoT T | TovooJesonuoJ[[ooovuw[[oo0oesr[[owoson[|[moiwiwn[[|aaoa[onoarT|onrr]]]
[em FC istoT r[7 ovaanr[[asan0we[[Tvwaoa[oosneio [[oooeJ[onswaT[aoosmaooer|] orn|]
C CvT e vT eeT [waT [[wT merT [easTe owTwa1eoaTa]]
sol Tom oan[oem[a9[onJem[aio mo |oir|
Ceo al TowrT[oooT[anrT[owrT]w owTw ie]
Pages
000624
"Table 12. Back-Caleulated Concentrations of Calibration Standards for PFOSA
Quadratic weighted 1/5'. All concentrations are. expressed as ppb.
[(e[C eeroonT|dgT,Tf[eooonson|Twovoa [[TTevawaTsamrvsoT|oiaoosrTooar[TToaaaTTTTooonoToaor]]] [[eormi]n 55TTeoiwooTe losw[Teuoowle|TTeosef|rsaearo Toao||TaoooriTTTeeoaaaae]]]] [CEnT|eTTeeveso[lvean Tiawmia[omrsolaror ow oonTaoaTaoa ]] [[oormn]|v7TooidoTaoweTToonn o sao|r aDaoorrr|TooareTTTaotorarr]]]
)
few we e aie a aTaEe e ae a C meel TTwolw asT T eTo w ewa Tareo TtoaTTs aae]]
om
Page 27
000625
Se
Table 13. Back-Calculated Concentrations of Calibration Standards for M556
Quadratic weighted 1x'. Al concentrations are expressed as ppb.
[C E eveT s| +Jaal[oww[w weE [w0|o0[w EwE woo[w]r]
[v[C oivenT || 3[Taoossee[[Touoanr[Toa2sie[||o90was|T|ownars[[|aowone[owoooo|owre]]] [mC C moT|5 ooe wn[[awm [[ooswe[o [swoon|[[wn0[mool w[[oawmro[oo0]]] [[vC vemmT|| 7Joa eos [T[owomor[T[a2as0e0T[[o0suss |onwwaeo[[|ooanww [[ooaomr|[os]iws]] [T oemT[3eeaanw T[owwo[[[aweoose[[[wosaiua[woworr[a w an aoowr[[or||]
--svT o]eT Te owT JooonsT [ [uwTTr |T aor[iaes [e T iwse [air|] I e ol TeESTTosCoeO [[0wIe6o [T oeonT[C wo[oaI[ [5TIo[Ta |O
ee Et
Page 2s
000628
re ass
Table 14. Back-Calculated Concentrations of Calibration Standards for M570 Quadratic weighted 1/x". All concentrationsareexpresseads ppb.
[L i oveT n|=+T|elvmw [[d wear[[ooaw [|omoro[[Noolar[|Eom[E o5i8 [EorR|asnr]]
[[[ oovmeen1 n||53 J|| vvooasn m[aaaes[|osooure[[[owmnoiao {|oosursee[||oiiooro[[aoaw [nan|erarr||] [i[ [ to |5T ast[[oT o 0nT|ossosr[[[ovw 00o[|omovano [[ow r oermor[[[oooisn[[[a o3on|n0o]]] [ mreevai 1 n||7Taevssoom[[aaaw[[[5oo0mi[[awosonot[[[oaaas||iowmn[[[oo3on[[[oa3mnm |ossrii]|] D)T [ [TT wT [aeamsn[[h ooernr[[aoo oosr[[|nora oe[oommooT[|ow snaor T[aanwn aosnr|]] [C se ollTo oonT e[]ewueT ss[[oownT n[[1wT 5eT[3er[T oseoTomT r[s1 s | I oswelF {Twro[[aos[I sarl[O 5oae [TE ooo[s aoETnT[saIa oiTsOaIa]Tr]
;
000627
a
TET Tar]wr Table J 15. Analytical QC Summary for PFOS
[rC oermmetmonote[] TT| Gsv5s.o83vopzpoT b| T n |Goow1v26irpepbT T r | Gpo3w 3v1opp]rb.r|
E [C ooEm [e 5[eoET
|m mT T] I
CT C ees[5T[sews 1 w |wwmw T T] e ]
E [tC eE mo [R 7T[sesT w N| T TwI] ]
CC eremo [3T[ee aarT Ta w mT T Tw ] ]
T esol TewsT |a eeT] i
[He erwaetl] T [oo a s T |oaao TrasT]]
CTTT]
000628
`Table 16. Analytical QC Summary for PFOA
[C C eam [2TT[ooawnwT T w w |ww ww ] ]
(tI am [5T[owe |n3 wm w | ]| (C evo |&T[oonT T|wm|iwe]] sm|7T[oeo T0w | 30] [eC ves [5TToonT T |mmn] mn] I sol oI w [NaTw as]
[e[ miealw Ta om [|wawerw a ] | e]r]
;
--_--
000629
Table 17. Analytical QC Summary for PFHS
-
Run
LowQC |Medium QC High QC
C1Tow wo]
TeeTwTw
C TwT ww]
C ToI TwTw
C TeI Tw er
'
CTTow[wr]
C ToT [ww]
ml Tw ew]
[mem all T Tiw w00e [a aans[ea] ai]]
Page 32
0010630
NorthwestBioanalytical
Study No. NWBS0014-5 ReportNo. NWBROI155
"Table 18. Analytical QC Summary for PROSAA
All concentetions are expressed as ppb.
me Lo] as [ae] Number| 450ppb | 1Sippb | 401ppb
[Prepasion ate] [05-Nov-2001 05Nev2001[05-2001
[osvovaoor[1[sot[si [7]
[[Te [ww [s ew |
[odorant[2[506 | wo [wo|
[[omevmo[5[eonor[|Tiww T|aaw|]
CF omo | 5T[oosT |ww| ] wm |
MC oma| 6T|eosnT w |[a a] ]
CT ove | 7Tw osT T [wwom w]
)
MT orea [5ToenT T| mm0 [Tonw]]
C TeT ww
r rr 1 r --T
[v T ase s [| ww [l wr |
[s [omo [ oo[f 20|
[wo | ws[es | ss|
[[oem | woisr | ior4c|awo] rs|
[weal [1T 26 [|
L [wwo [wT ww]
+> 25% deviation fom theoretical
)
0008631
Page 33
Se os
Table 19. Analytical QC Summary for PFOSA
[(CoFtrosorvmamosn T[ aNmummbeer||7 s4.0i0psspb|[r|0 i1v150mvppb][|0 i5v40e00sp5p]b|1
CT EE CTe EweR a]
C CaoT[TT 5To0e
T waar]] ww
ECT eCeE [ReEe oEnT w I |Trea|]
CC C ivevmor|7TTooswweT T Tw owrT i]
Cr oI mer |Ta 1 r w E1 OIa 5]
vseol el
TTTowwm[w ws Tw 0]
[C ComeaellT T Ts n[wosa ot5T ] wi]
J 000632
=TE [Es[ne | Table 20. sions Analytical emt QC Summary for M556
C[oFmomponmTioTntTu5e4.0]00p--pb|[Goo1so500nwppsb.o|Grtw4o0n0 eprpb]]| [oon 7Teoww w wo a e ]
TenTe a] C E T T ERTo NoEwT [ TNww Ta wNe] Te [ovveemn[|7eTw o0o [|w wae a s] ] ] [T omare |v e ao |w ww e] ] T oe T Te oT |Tw Tw 1 ww ] ] [wsm eol]w eow0e [s es nn w] ] mo] C we oTrewmT T[awo T5w] ]
000633
`Table 21. Analytical QC Summaryfor M570
EE er Ey [{oPsrespoartiaoonoD l[71Tu aNowr200[1 o 05 ww00[ 1[s 5o| v201|
[L oon[72T[essesT | aeee| [wawn|| [No[ vator [T 37T220a 5T | w ia w |aas] i]
[T [Te wTw |
[[ snow[T 76 Taoe | [hwim [e |wao2 ||
[s[ vozoor [77T Tem | hww ww [|sao]
'
[r[ odovzoor[T 7s[7ae [[iwem | a |5any ||
[ [T 1 e [w7 e[e oi]
[ [we TTs oeweT [ sw o n | mw0n|]
[m[swme T Tir[[oos esr | wo||
L [m T7w 2o a T [asw l | ] 50 |
000634
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSOOI0--115455
II al ol Mal al Wall `Table 22. Serum Study Sample Concentrations All concentrations are expressed 2s ppb.
Name
[[iisossT [anr s TT<eLii0o0o((10o0n)[S0t0sU| S| 4e 73 | |<rwosqase[<<ottoo@o@ms]n
ios wsTatoo [ssIme Teroq oo]
sn te
| als | a0
||<5io9oig[lm<iooooaessnn]]
ll
iar] 3a] ra
[Ise [ass [is[7558
T<L00 (100[<LLoQ(sh <1060 100[LLOQ 50
295 336
| 267 | 323
T[ettttoqoo(2a.5m0 l[400r6a(1s63])
[sss[32 [se T7523
<irro0oq((0o0o[<<ttiroououssnn||
46 | in 467| 3a
[<mooes] [<iioq@so]
im im
|
[isso[74 FIs [553
T<Ll00(,00)[ aoa(0)
241 [396 150 | 394
| |<i7t005(1[36t) <oLLooo(@5s0n)[[<<Et0o000
5%] on]
[ise [oa 11343
Teri00
0] 150 [ae
| saw] am [aa
[see eis [[iiibsiss [[ssaess
TTa<t1teo00o(o00o[s10s7 [|73ise T<1100 1.00)[SII0Q SH _466
| | |
sn soo
152
|sor [aa] [eiioo@m] as
Jettoo@sn iis
j J
[ [H8E[5ie7s TJce0oq0u(1o0n0)|ia0e00|]
sei 284
[iss [aes Tarioo(100)[<L00s0| 42
||<isi0w0 38I]<oLoooeason]| | 177 [<io0eso|
i| Ta] is |
[[i[issssst[The1 si TTe eeiio07 aq(tLoo0o< o0)])<"L1 a20Qsn1t | 503|_0 3_231s760|<|1<tsII06a00((13366[)<<<rLLLiL0oo0ao(3s20o:5)[)[<Li0t6o30a55o00n1]]
[[Bisse[[iassTT1<1ti0000(01.,0000)
350 488
| |
12s soi
||<iti0s0(s36[<<Ltrroo0osasoo|
[ise[507 [<1L60(100)[SOQUSO 949 | za [<itou@so
241] is] 12]
FisTies [is[252
T[e<i0t10o0q(1000)][<02Q0 S[04109
| |
210 10>
|[<e1r1t0o0o2@s5o0/0o0 r03]]
[ise[er Temoqao] 15 | 63 ||<8r5o0es0]|<toooo)]
[[Fsies steTTs iiemzs TJee+tr1r0oo0oq(qq1.oo00n) ]<I1T0eQ7z(1| | 30121a56s87s_| _||<3t1o6o9qsn||]<LaL20s0s (25| 0]) <LiLi0Qes(10]]0)]
[ses [eo [ose Tio
Tetoqoo] Tetiooqo
550 | iss |
sas | 2a eis | 213
[<iooase] sie [atooas] am]
L166| 96 Tetoquon] 16 | si | wa l<iooase] as
NOTE: Ti(nhde2iv5mi%edutfaholordrPeasFucOlcteSpmAtaaaynncedexPcceFreOidScAtihAes)QaotCfeastchtcheeaptttatrahgneectmeecoacnsrciuetrneetrdriaactoinocne.ntTrhateisotnatfiosrteicaaclheQroCrmaasssotcibaetewditwhiitnhan2y0%
|cSucrrvuesm msaamyplvearryefsruosmftoersuPlFisOoAb,taPiFnHedS,usPinFgOsSeArAu,m PcaFlOibSrAa,tioMn3c5u6rvaensd(sMec7R0esoulbtssiannedd uDissicnugspaliaosnmsaecctailiobnr.ation
Page37
000635
Nosthwes Boas!
RSeupodNioo MNWWOBSROG0L-113535
Table 22. A eh Serum Study Sample Concentrations (Continued)
[FoNoere[57 [[sssos1 1a7
[Ss1i2oe0o0oa.ao0mo0|l[w<s0ae0oa0o1ut5is0oo)][<L0000(1| 3%)<Ti 00 038]|<-LLio0e(a3m0[-arisoaatisg]
[[E ForTEonm[[aessT[<oioooGnoono[T E ]Saoses(3E 0 as2Y5ne7rO[T|iiiams) [a0i[Jia7aoi7ioc.moo1atenm)]]--Ttaoon ]]
[[[rFolTosEmreTTTiaelo si TE<<<rttiioooe0o0Gqamoomnn 4S1IE10oYe30(803:00|7]NEi3e5Esw2C{T|sa7ioosET)||E<s<i1ctiii7ooo10qo(c0taa)unm[i <i5 iiooasu] ran]
[rToEm ns E siooC aon] E2Ea ewTTsNJ7 aootXem i]|
[[3FasseT176209.6 [Fmms 65510
I|<<<Ci1ro00o00.0a0..m0000a]<tL0o100a00(t(53m00])7]_2es91o7s Termooasn] 16 [5m
|||it30s309s4"30J|]a<[t1i0o00a(tG3a3n0015ot0oe8afrroaa]] | is Tart
[[) [u8ism8es TTZo5i0se2sTe[io<irrod000on0.o0o]0[[<<1s200i0(z1.[500)]sa4m2ss |a5s 3J4a0io[<<oriaitooaa0(anaanlnmsa[i!rt3aees4eeen4am]])
[sI sws TTes sT TToerooonaS ]ml2inss ||Y osomrTi3Y e6 JTaixlmso0tmanmilitioseua]]
[[ForFosisstT[ois1 sse T[T<~<ririiooo0o0(uaoomon[l[<r<coioooootssnnn]]]
iassss | aisns a0 Tiss
[os TesTuocuml 20 [oT 3a
[J|<isiiiooooagtaaeammnlamTiaaars]] Taiocon] s
[[[oBlssrsTTe2i7sTTs<euirioooooodaaoomoo]]<tsisoieossm|] sesosx T || si 4as TTdaiiiiiocogaenennn]|atireoeahet]]]
[[Bli1ss3%oT[202s1y7TT00r1o000o(0n00]0010020a3103|]052s0ss0o Clio TsTertooaoo sa [sm
|<Ioi0or30T]i<liooe [elton(36 og
anatooaatio]n] tat]
1si Tatiostoam
NOTE:
TSh2em5e5thlordPsRcOsSpocaend
RriOe aSeosfAhae rheenmeesesncsocemTrnioonfmoc,h
QCotkb
as] wiibn22200%
individual result may exceed the QC acceptance criteria.
J * CesSerum vary om sample results ess obedience for PFOA, PFHS, PFOSAA, PFOSA, MSS6 and RoM570 `obtained nl ol using plasma calibration
Page 33
000636
Table 22. Serum Study Sample Concentrations(Continued)
[il1i1e4[0s2 TStasrT[asutcoouo]<a0os| n 663575| | issuo Fee[204 TeLt00(100)[S00(30)]
Temooass| Termooasn|
my] sor]
TO EE 299341 {Toe [dos_[<L10Q(1.60) S100(50) 336 | ws
[<tio0aso]<LL0Q (1.00)
7-5)
|
<tioa a 0) ireair]
Filsor 06 [tos [0
T<i1i0000(1000)]<tr2o0a6us| n 375070
I YE eT)BE
|
700 ass
Termooso] tor] <troo(eso[ron am]
[si EaN s <tT oo(oY n[333
ST 71.Y0E))RYrTE | |<itoo em] im [<roosn]<LL0Q (160)
[iz [iat [ila
32a6sTT1010010(010)0[[SSLTL000Q M5S0D]]
314 444
| |
57 a0
<tiooeso ast [auto(50 [S0013)]
0T2000(1.00[S00U0) 344 | 63
[[aissT2e1a T<1r 000o (1.00o [S0m 0(3| 0)] 29458T[e <i0n0 3J0[]ae<tciiooeaataesnsn[]<<cri1ooah atits]n]]
EE EEE
ET)7 ES YY
NE EX
[iissT7263 Tatoo] 2m | as
17.3) | issJaEtiXc .)RT
:[Flilaa[r77e57s2 1T1et1t6o0oa01o,0o0[l St0o0s0|]
227 676
| |
200 697
oasnl Th] [<iioacaso[ iss] fatoaaso] 3a]
637)
Fis1 313 EEE
1142[5 IST
[T<<LI1000qY((11.U0000)))[N<SLE I000QT ((is5n]] 43.9403| Y |<I50Q5(1136)[E <<LLiLX 0000 3)5[9000100]|
F[haareT [i 2s 0 TT<eitiooq0(1o0o0)[[ssooeoissn]]
260 | 6:2 89% a6
(250) S08150] [eioa@snl ads] Jaioo so en]
EEE [iki
[297T0600(1000))[SEOYQTH3D]E atB |
[Is0[4111100(100)[<LL0Q150) 405 |
sJ rs [<7tioXo ) so[1a]| 215
[3 EE 6 TTaY too(Loo)[<LLo0U0)
256 [170
[<tt00250 [sion(roo) [<tiooaso agi
I JTX)
EK [sor Teimoeaoo]
EETCET 1s |
6%
| am
Fis ae Te0i0] 314|37Tis
<LLOQ (230) Taiooes]
615 iis]
[ite[196 T40001.00)[<I0Q(130)
282
[<itoo |<0100(39) <LLo
so [00(10 30/1100 1.00]
Page39
000637
Table 22. Serum Study Sample Concentrations(Continued)
l i l Wl ilWl [sFrEToers [[00o0a.t00]<05Q950|] 3a66
[ows[100000 ss | 556
<i60036]aoa ||<isiomo30][<aLriooea(a5sm]
oa] 1s
FI ise FlinT7203
<LL00(Lon [<00 G50] T<10000.00[<L00Q 50]
358 | 205 430215
[<tioaas0n)]<iiibeassio]] [<rioaeso]<roatas]
[iss a2 EY
e00e0(C1.00[N<L1E00(50)|
1st -
|
265
[<itoq so]<riogian] 17)
[ites m2 Fs[117
T<0000 4100
((11.0000[<<LE000Q(SSO 012833
| |<LL50701(136
<LLoq [<Ito0
(2.50) (250)
<CE0a <LLoq
155] (Lod
[Firssser [ [02 4 <<i1i1o0o0((11.0000[[<<LLrL000Qu505)0]) [lies| 154 T<L00(100[<EL0Q 50)
345 295 278
|[<i73030(13[0<<tLiLooQo(@2s50m)]<<LrLoogg(aLasos) ] [<it00(36<Lto0asm] ii
[s Pisos [|65687 TT2e1w0o0o(1o00n)]L0570s0[]503.s8| |i 269
|atooesn] J=rroqaio]
] za | ast]
[[sHiz st[559008 <20111000001(1.0000)[[<<LL00QQ(15500)|[428.475 [rssT7506 Tetoo(oo ass [as
| 130 |<LE00(130
[<rLo0(s.50)] <Lo0 (2.30)
C00 (00 <LLOQ (100)
| wo [<moo@sn]<ioo on]
; [[iSisss[0 6TTa<itioooo(oo
ain te
|
ais 24s
I|<<iiitoooo(w3e8<tLooaoeo]<Liioad1s00]]
[lisse 1ios [liast [7b
[[e<00t0000(1.1000 0224001| | 134123
[|<<Lt1t0o0o(1u5s6)e|<LLz0Qe(2.5|) <LCi00 (m1d])
[[liasses[[4o6o1 T/<<tLi0o000((10.000[<CLi0sQT30|),
376 481
||<ii5o25o00|[<<titoo00(@2.i5m0 ]E00s(s100]]
EO EET
EYCeYYBEYY TS NC
TYEXY 7TEX)
TI |
F[[liT ie ssee [[77216s7"0 11e210000((11.0000[) 5 CO214Q56U5S| O| 30e0 3a2ss | | | za1s7mo00 J|[eeatrirrooooqG@sssooo]
ror] ie in]
[lise [irs [lise [7556
TT4<2LL0000((11.0000[<E2E00Q0(3| 0) 424909
||<it040(136)] <[Latrot0oao@ssoo |
zw] 17s
[iE sa [E eerSTele t000.Y0S0277
ES | 6s |
1J 5 [onaYsEo|)sYmT ]
[lise asi Fito[320
TT0e20000((10600)[[<1LE70Q7(150|)
396 181
||<L7C001(136) <<LtLtoo0o((22..500)[<Cit0000 ((116000|
Li Tey T1200(100)[E00 501] +22 | 356 [elo(50)C00 (1707)
individual result may exceedtheQC acceptance criteria. ! * Serum sample results for PFOA, PFHS, PFOSAA, PFOSA, M556 and M570 obtained using plasma calibration
_m
000635
Northwest Biosnalyical
ReSptourdtyNNoo., NNWWBBRSO0I0--115455
Table 22. Serum Study Sample Concentrations(Continued)
Al concenttion ae expressed5 pb,
[rann| Tss al <[ti<ooqL.0L0[O<uiQoe(5L0]OO5s6[o0<| |LL3e O66QJ|(<<tLLiioSoa00G@as|m0| 3i3er
[iFiss 7e[136r5aTe0t000q0((110000[[<<LiL00Q0((510.50332519
| 5m Iettoosm | oy] |<Ii00(139 |<Lioq 2.50) roaiam]
[isn[ns
Files[asa
T<tiooaon 1a | ev | 5p
T<L00Q(100) [<CE00(50 sat | 650
Jaiosesy] i1p34 ]
[=iio0aso] ism
F[iossms [[a2e6s0 TT<00000Q0(1000) [<06I0Q9(| 30477262| | e ie
Taiooasol isi] <miooasm ino]
[luss[zT1o57aTTa<r10o0o(1a0o0n)[<112050(015[0|es3.i15 __|[<L0006(136[|<<iLtIo00o2a5s0n)]S1 LOG(]|
Filsss[7725 [sssT7506
Teitoouon| 766 | [1100100[S00 (30 |
720 421
[<tioousal aw [im] |57m [<oo@se] ior]
[Lsl8a6r| [7557138 T [11S 00O (100)] [<LL304001| 50] 366605
|
155 3a
]<IL00 (2.50 [<T60 (0) [<iiooGsn| 3m
[iss [52 [1158 [214
J<trooon| 1s | se T<1L00(1.00) |<LL0QUS] 301
| 5m |<0100
[<ooesy] re] (136]<LL0Q (50) far
)[10[06 [is ois
Tattoouon| T<ttooon|
261 | as as |_tos
[<ioouaesoso] | sam [toes]
3s] iso]
[2 502 Fie Tas
[<t100(100[<0Q 30416 T<tioouon|12[ans
[5.2 120
[cioq@so)] [eiooaso]
Ler] 1s]
[ss m0 [riesTse
T<tiouon| J<tioouon|
ax |_ses |e aiooesn] is | sm 1515 [<oo@s]
zm] iar]
Fs[775 [ior 1764
0000] 1s | 1100 (100) [<SLL0Q(50
se | 550 895 | 227
|<1100(250)[<LL0Q aH] [<Lioq aso] ia
1498 [5a2 1499 [570
ISLLoquon| 251 |3m <LL0Q(o0)| ssi | sis |
27 106
[<ooeso] [<tiooesy]
ies] im |
F[s11o50r0T17210752 1[1<011000Q((11..0000)) [|<LLLLO0QQ((115300))|__2|2__3196
|<I100 (136) <LLo0 250) 160 <L100(136)[<LL0G (2.50)|E00 (L651
[se 77561 so [505
Tetoouon]" 1st | [<0t00 (Loo) [<L0Q(50)
6s 352
| sos | 35r
[<itocasn] I<lt000s0]
6s] Tio
fisos [ios <ti00100 [soe "a0 Teitouon]
229 210
[ai [35 | 30 |e;
Jettoqasn| [<itoapsn]
zor ise]
[sor 752. [68 [263
T<it00100| 231 |_38 T1000 (100) [<LL0Q(L501 257
| zai J<tioq sn [<ii00 36 <Ltoqa0)
ion tas]
NOTE: T(h4e25m%etfhoordPaFcOcSepAtaanncdePcrOitSerAiaAs)aotefstthheattatrhgeetmecaonscuernetdractoinocne.ntTrahtisotnaftoistiecaalcherQoCr amsussotcibaetewditwhiitnh2a2ny0%
individual result may exceed the QC acceptance criteria.
! * cSuerrvuems msaamyplvearryesfurlotsm froersuPlFsOoAb,taPiFnHedS,usPinFgOsSeArAu,m PcaFlOibSrAa,tioMn5c5u6rvaensd(sMeSe7R0esoubltsaiannedd Duissicnugspsliaosnmsaecctailoinb,ration
Faget
000639
Table 22. Serum Study Sample Concentrations(Continued)
[ [ [s SSI wl To ay 6 TT[4<a0Lw00o00e((ti1oo900n[]E105059G9A| D|] 516e622 | | | sn3[5 ai<torooonasmowetgas]]
Fist [ses HEBTis
TTeetmio0o0 a(1o0n0[S05000W[D]as507
ser | 30 | sw
[<tio0oon]amon mm] [aro0ean ser] emooasn] 130]
[ [isIt T [03645T<T1a1t0o0o1o.0n0[|<Ci00sQ(s30| Fists[576 T<0Lo0(100[<it00050]
212 297 585
[eiiooqag)[]trogen | ass [<tioa@sn] | a3
286 | 154]
[HET 62 [Isis 850
[<iioo(00[<o0aso] Tlboo(100[00150]
9s 157
| 25 | 37
[ettoa@sn| Tas] |<oaasn| 14]
<LL00('s0 [E00 (1a5]
[is Tos Flo a
aT<oiieoot(ooon[<L1r:ou2s0| )] s2e10
| 335 eiiooasn] |<iooqael<toaesn|
1a 2m]
Fis [lisa
es T7562
TT0e0i0o000(10.000[E0i00s(5165a3a6
||<00n(i 36 <<LrLi0o0(o2:w50n[[<iLLo0Q(s108])
ETE [sae T7301
<000C 0(1.Y 00[<C00QN (303E 48 |A
Fis [5T<ii00(100[<r00u50)] 361 |
J 1TEX YR 17 [<Looaso) 131
ETH oad]
) [lise [isa
eos 184
T[e+1u0t00o(o1o.0o0[|S0200m15| 0] 2s4s2i| [<01e 00(36T[e<<ulLiLL0oooa((2:ss5o0n[[[L<T6r00o00g116a00n)]]
Fliszs [50114200(100[<LL00150 4 | 5 [atoacsnl a5 |
[iiss HSL]
2i0o23 T[1<200000(L(0100)0[[<LLoL0oQ(U5S0O)
348 299
|[<I2T7001(38[[<<iitooq0ps300]00214500]|
[lise[oe [Hiss[355
Tao00o0 te [a T1400(100)[<L0QSD| 188
| |
21s 14s
[aoa] asm] |<Lto0 (2.50)[<E00(10)
[F[liiiissses[[smiss2eTTT11022000000((101.0000])[[<EE0100s0(U03)|0| 262456352| | |<isi10e0(p13[9[<aLt0o0(a2.50][<0110505100|]
[i538[354 [lisse[525
T<LL0Q(L00)[<LL0 150] 238 TL00 (100[<L0Q(50440
|<1L00(136) <<LLLL00G0(22.3500)[<L1T605(1]% | 23 [<I100@30 <LL00[100]
[listo T7157 Fler [ae
T042100000((11..0000[[<<tLLLo00Q(1550)0326265
||<012010(313[9<t1t0o0o(i25o0)l<L0d6o(100)|
ls | [HIZS (mils
409 62
T<[L<00I(1000[0<tLQo00s0o [5L57o79q|1(5sae0 0s ]Je[r<tioooa@csso]n|
200 zn
52 Teroquon| tes | as |<iioouseler
|
oaoes]m
! * Serum sample results for PFOA, PFHS, PFOSAA, PFOSA, M556 and M570 obiained: using plasma calibration
pagei2
000640
Table 22. Serum Study Sample Concentrations(Continued)
CT TE
EEE YET
YO
EE EN
E EENEYTE EE
GH112[ 83] 2 Jsoeuo<tioqin] 3s | is Teioons
Ee i
|
[CHE] [RET
4[4LoQUo0 520 Teuwoe on]
50 im
| |
369Tim [<ito0(sonl<Ch2osi5am]] ass |<iooazal<tio tan] ast
[GIIz] CE
[CRD]
05 [<1400(100)[<L0QUF
741 |inn YJ YT
[<7ttXoa5s)n Riro]
a7 T0000 525 | ls [i000(39 |<tLo0 (250
[CHa CTE
Tatoo is TY
|4sTei Jatoousol[Sotneatm]] NSNS 7:10) ME
[Ghz] [Giz [GHtIaos]
ost 20; 163
<tioqion] 506 | T<1000(100[ST00SD]
aor 559
||5i100m(38][<<ttotqo(o:as5o0[Traoeo(tiad])
T<1000(1.00[<EL00(50)<LL00(LH 753 Jetioqcs
[[ouStiHasIs]T2510.04TTe<rLitoooa(oLoo"oams| 1 s9a6e[[<3I00m0136e]<mLic00a(e25s0o[] L1o00mr1]]]
C[CEHIE]E 154 C |<L10q) (100[<CL0Q(50) ) [SHIG0] 52 Tattoo(oo 177 |
2.55 eas
|<ITY00(J136)E | <LLoX 0 (2.500)
RE A | E00
1557]|
ws Jatoensol
:
[SHIDO [Gutisoa]
21 157
Te<0tLi0o0a((1l.0o0o) [SE2L06Q(5181]
ess
|3s
Jaticoqsn]
tar 26]
3.17 <T00(136) <L000(250[<L0017]
C[TCEHITT 505C [00) 100E Li | 37Y 3 J<ii00(36)]<LLoYaX0)[R <Lr06C 1100]
[SHLBOS 117 TeL0Q(100 22s | 344 |<iioo(39) <rtoqsn| 1a]
[SoHuitors|]5se7l T[a<LtLo0oQ((LoODo)[lSLL2O0QsUS| )
339a2 | [<11i6s0(136)Te<LiLoOo0 Go5s0)o|
140] as
[[CGHaIBoI]]s2s127T1110000(1.000[]C1EQ63| 6] 335040 [GBI]100 T<10000.0076 | 150
| |
1s 30 sm
[<LLoa(250 [0611] TTeeirotooaossoo|[ iar
QB Bd [CHIBI774
T<[100< 0(1.I 00[L00Q 0(500( ]) L 430487.||0 <L3L00 Q7(136) )T]e<[ LiLt0oG< a(2s.5o0)ELLa0 OQnm(Q T0]]5]
[[CCHHIIBLI]] 5216a0 TT1<0100000 (11..0000[[SLtLLO0Q015500]] [SHI].T<1L00 1.00[StL0010]
439 | 275 3481 | 211 386 Tas
T[e<tiitoooo(ssoo[]rosamia]] [<tiooaso
18
(SHIT"572 Tetloo(Loo) as | 3.56 [<00(30) <LL00250 [S000(iam)
feats
000641
Northwest Bioanalytical
ReSptourdty NNoo.. NNWWBBSROO0L-115455
lal ilt l Wi Table 22. Serum Study Sample Concentrations (Continued) Al concentsionsaerxpressed a pp.
Name
GHUSI] 31|<LL0Q(100)|LLOQ U0) 42%
255 [<o0asn] 15|
[cGiGliHH a]II a 123111 2.0s 6423[|2 <<TLarLiO0 o0Qq(0u1] e.[ 0o(0lo])o) |5<L6L8 O6Q 1(1T .| 50|) s5e 6os"U | |5a25m m7
[<ii00 aso) | <Li0q (oo) <tooas [te]
CRIS] 109[<0Q
[GHIIs2276a][<100Q
oo 294 | 212
(1[ .00) 26 Tass
|<i100
| 5%
4| 36) <LaT005[33 t<Ie03s(15] 5)
[aiooasn] 3 |
[GH17Z 7 CRIS] 456
1100 (1.00) [<LLouon
<1 L001(30)|25 96||<EeL0o0 (136
<LL00 ([ 50) ts] [<ioosn[20]
[GHiGaT] 66 [GHIIs28] 564
[<10Q(o0| [<100Q (1.00)
231 | 838 | a3 [<LL0Q (130) 335 |<IL00 (138)
[<iroo@sn <LLOQ (2.50)
[amon (100) [<LLOQ (100)
(G[ HII330|G2172H 83 [2[1Z <0LL000Q (1.(01.00)0)[|<LLLLOOQQ(1(.L5500))]322|<LLOQ (136)
<LLO@[ 50G) is] <LLOQ (2.50) |<LLOQ(1.00)
)
NOTE: T(h2e25m%etfhoordPaRcOcSepAtaanncdePcrRitOeSriAaAt)atoefstthhaattrhegmecoanscuernetdractoinonc.eniTrhaeiosintifsotriecaslcherQrC amsussoteibaecewditwhiitnh2a2ny0% individual result may exceed the QCacceptance criteria,
/ * rSeureusm msaamyplvearryesrulotms froersuPltFsOoAb,aPinFeHdS,usPinFgOsSeArAu,m PcaFlOibSrAa,tioMnScSu6rvaensd(Mse57R0esoulbttsaiannedd Dusiisnugapiloansmsaecailnib)ration
Page ds
000642
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSOOI0--115455
Figure 1. Representative Calibration Curve for PFOS
AnisReRparmasison heozdon15Q:2UQA0D0RaA1TIiCC l-mWeoign3hi0Sn0gnForr = 1FvOoS3 5)
2s
g20
2
Bs
fu
Sos
00 0 0 we mm me mw am Nomis Cone.
Figure 2. Representative Calibration Curve for PFOA
)
AaRReogrmas snionl! eaioodn~15Q-XUNAovD2R0A)TCIaCl-bWreiiognhSinugndFaar o=or1P7FO1A (5)
Qusdric Linit= 4270
3s gs3s0
SB2s0 fo
os 00 Rw ww mwme wwme
Nomi Cons.
Pages
000643
Northwest Bioanalytical
RepSoturdtyNNoo. NNWWBBRSOOI0--115455
Figure 3. Representative Calibration Curve for PHS
AostaReRpnrasieon tlhydan=1Q5-UNQAouvDa-d2R0rA0i1TeCIaiCisWtme=iio3ghin0iS0ngaFdorrf-or1PXH0S3pp)
2s
b5 5s0
50
bBios
0s
ao
0
P)
x0
0
"
Nina Con,
Figure 4. Representative Calibration Curve for PFOSAA
)
AntRRumepi6rssiyconeedsons15NQoUwA2D0R0A1TCIalCib.raWtieonSnagFsosror P1R0O1S3AA (5)
Qed Limi 38
s
i5
k
oo
"
P
0
"wo
10
wo
Nominal Coe.
000644
Pages
Northwest Bioanalytical
ReSptourdtyNNoo.. NNWWBBRSOOID--115455
Figure 5. Representative Calibration Curve for PFOSA
AostaRReagninolnyMhodn 1=5Q-UNQAoDvuR20Ae0TICLCilmiewteai2gnh1tS8in0gaFanefrrdP1EOs8SA (pb)
'
E8 .
:
2:b
' 0 mw
wm 2% wm Nomina Cone:
am
we
a
me
Figure 6. Representative Calibration Curve for M556
)
AvayaRRegnrsiaolnyMzeethdoodn=15Q-UNQoAvD-u2R0A01aTCLIiCl-dmiWtaering2h3aiS1n0ig Fdrarfo 1M-SS36 (5h)
2s
20 I
bs fo Szos
o ww mo mm x ww mm Nomins Cons.
Page 7
000645
Northwest Bioanalytical
ReSptourdty NNoo.. NNWWBBRSO0I0--115455
Figure 7. Representative Calibration Curve for M570
Asc!ReRgurmsisonaMadaon=1Q5bUNQuAodwDoe2Rt0AieT1dILCCimoibtWae=ii1g2nh5i0Sn8gaFsoorJSoTrOy ot)
' 3i.
b * | 21
|
0 ow wm Ww mw me wm
Nomina Cons.
)
Pagaes
000646
Nordwest Biosys
ReSptodrtyNNoo.. NNWWBBRSODLO--115455
Figure 8. Human Plasma Blank for PFOS
FEE HH
[pErS-- =
on
Emil
EE
EE
i
Eon
Jaa
:
ei
BEE Ey
!
3I
fm es
J----
a-- Ea
iia oa
mii BE PA
-
BERANE SUE Sr
Pages
0006437
Northves Biomalyics
ReSpaorytNNoo NNWVBBRSOOL0--115455
Figure 9. Human Plasma Blank for PFOA
-
Sn =
PE E m = --
PHY B = = Lb il neTh
Ee wot
=Ai
=
iT 110 Iitr
Fi
EE a ARRAN ERNY Sy
3
Ta e rosS
PrEr e an E be E =d3 re
-- ===
CEE
;
i
:
*
a ta dn Th ON Ta 0 Te bs
Pages
000648
[---- Figure 10. Human Plasma Blank for PFHS RStuedyNNoop..NNWoWBBRSOr0L0--1t15455
pB n toeeeE nei) s ima neEdf .=
wn =
oe mm----
.
Em]
Te a
:
+ J: iE
fae
RRA ELAR Sy
\
= Ee) 3.
-- mmEEEy=2
mere
E-- =e]. His ol TT
: = | ey
SALLE ARARE RL
Fagest 000649
Northwest Bioanalytical
ReSptourdtyNNoo., NNWWBBRSOOL0--115455
Figure 11. Human Plasma Blank for PFOSAA
= eS wo ee ) . m 3 zn d 3 SIT aEnN=EE ae ma racememe
eR
f pB= tE eem amrm )o
Ea El
JHlaeeleas obienas|| e ena 0 s agx
HEE
i
opin pin Rome ERR RRR Cer
a
ear coro tem
ill
fee
efe eaml ie] Ties 6
Jia
4
i
5
;
5
-
EEER EEEE E
000650 Page 2
Northwest Bioanalytical
RepSoturdtyNNoo..NNWWBBRSOOL0--115455
Figure 12. Human Plasma Blank for PFOSA
poE i ro es m m) m= Sa adh3
frail Sa=mII
EE
--
en
-- ER
te
Emmy [igenteens
anee m r
BEEEwo
h]
TRE HE RR RS i -- maan So = Znmo felb=.2
mm
Sa
ffaaa]eal
[onc= en]
-
EEE EERE
000651 Pages:
Northwest Bioanalytical
RepSotrudtyNNoo.. NNWWBBRSO0L0--115455
Figure 13. Human Plasma Blankfor M556
mo oenmenr tos
=
oar
Sm apSEenssl
rr rmvente
ee
oB -- r ea fare im
TEEl nl Tia
aCnla eeeEisn
| fo
Ze
M1 ar siLm E
:JAIEHiSARHTl ORII BL |
SEEN ERA er
) ft --e ----n noa a EaunuE yre3ls240 FR
Fr-- a =--] " isol |
ited |= 2
SELL GA EG
)
000652 Pagess
Norwest Boni Figure 14. Human Plasma Blank for M570 RSeupodNNoo., NNWWOBSROO0L--15855
=
takDIOL
TH=
Gerad 1d 10
e ErlEee3y
----
--
atic Le) i wf olBN mi
d ARAMA L RC
) = ELE we NEES hr
meme
Boh fio ome sone]
.
3)
%
fem --ea
[anc
-
HERR ER RANE Ser
)
Fagess
000653
Northwest Biosnalytal
ReSptoryt NNoo.. NNWWBBSOR0O.1L54-55
Figure 15. Human Plasma Blank with Internal Standard (QC0) for PFOS
PEs
Ss 5
-- ET eenedr on
T. eiiaetl a : l:e
TERRYEr
)
T= e ro S
er on wBeEsEt2
PEE
F--
a B e= n
;
Tia olf
THRGER EERE
000654 Page 56
Northwest Bioanalytical
ReSpotrdt NNoo.. NNWWBBSRDOOL-115453
Figure 16. Human Plasma Blank with Internal Standard (QCO) for PFOA
e [----r -- e
= sm ov8 ate 0 ~ 0en
Eatmc aFedn
Hr
tn % a
CHER RR EEE A er
)
[T-- mE e mi Frm eefeme =
ws= :
eT
rn
|E =fooc=_a Fn |
THGR DEE RAE
J)
Page 57
000855
Northwest Biosnayticl
RStuedyNNopo.. NNoWWBRBrOIS-Ot1154-55
Figure 17. Human Plasma Blank with Internal Standard (QC0) for PFHS
= --a em m H SoH drE
e m_-- n ImeE= E l
mr corms mee ~
on
E= S E r EE ai Re
el TR IR 1
ema
Rl
7DL FB A SCA RET E AELE Ser
)
= iH
--_--
mma]
4
Ammen
[eoEes--aer] ]
( onp c m gn)
2 eE
TEAL ER BASE Er
)
Pagess
000656
Northwest Bioanalytical
ReSptourdtyNNoo., NNWWBBS0R0O-1I54.55
Ee =E=se= f teem Figure 18. Human Plasma Blank with Internal Standard (QC0) for PFOSAA
-- eee nT ESEN=EE=n3
EE
Eamelel s
3
CEE ao me a
)
= pots fsI
-- SEES
--_--
eed
mse amon
~
ren
EEEE-- E u. n . Ere s |
; : fre
CREE RAGA
Pages
000657
NorwestBismit
Sui No.Nwasoo.145
Figure 19. Human Plasma Blank with Internal Standard (QC) for PFOSA
_ P= ==--=--tEo2eo--hEt==sE:k: To BB) 3H
EEE ol
AA
i
! dl,i TOLfNY: TklHEAL
Che NRE
er
)
= == c5 a 5
mm
--
Ee=
ooc=|
SEES SER Se
J.
000658
Notte Bioanalytical
ReSptourdtyNNoo., NNWWBBSROODI-115455
Figure 20. Human Plasma Blank withInternal Standard (QCO) for M556
eg eeeseeeeeeseesmn. Ee 3
--_--wom orem meee
en
HH lL El
Emel |
wm wil
wTs m
Fo Tol
il | il | bl
i
fil i
CER ELSE RARE
!
I T= Ta nEeEdE
_ oan an = enaa3
oa r--
:
Biees=]
REET LA ay
Paget
000659
Northwest Boma
ReSptoryt NNoo.NNWWBBSROO0L-114555
0 Figure 21. Human Plasma Blank with Internal Standard (QCO) for M570
p------=
--
Ewell 0 fe
ET [emi] A
Spi2s i
mmm EGER E-- LS-- E S--r
.
)
=5
-- Tn egy
--
==
3
foe m a] [anc Jn]
ie
TRERREEL Bh
J
Fages2
000660
Northwest Bioaralyccal
Figure 22. Low Standard for PFOS
i--_--d a
oEmenm Eeeo=n
Zioa, _--
WRe EI RdrEo aw
ReSptourdtyNNoo.. NNWWBBRSO0I0--115455
a
Eee = iesa
So
L Ee |B
,
P-- P=] = -- SHEER-- ENT ey
_ ms are momen " rn
E rE-- a
2
iy
= [eoc=- Fil
ERRATA Ry
Page6s
000661
Norwest Boma
Figure 23. Low Standard for PFOA
= oEfee
.
Seen Zu
me=
RSteyNNoop.,NNWoWBDRSDrOL0--1t15455
=a a
Brisa
)
E ==E =a Sa e RE REReA
-- EE
Ei E== R
Eo -- ge i fT
==
Clie 0
So te i Th Th er
hess
000662
Nore Biss
ReipoyrtoN.o NWWWBBRSOITO.11913
= = Figure 24. Low Standard for PFHS
Ease
Ey --_--
_--
BE pe EE]
fens 5]|
si)
i&
senassiEes
fac
;
Fae
)
_ T= -- EEsEE -- AR er
e -- EEOe EE=ERk r
EBEeEtE e
aSer
EEE el
SEER RRR NS er
,
rots
000663
Notts iol
RSeoprroo NNBaRst11455
Figure 25. Low Standard for PFOSAA
_ mE= FEnmeB n,) Sr5 SooEeIieEd E--_--mr eee= orn
CfEeEmmGfe
LORi
i=
Eh ENE E Shr
J
== Em E =E= EE =e Yne
-- e Emme4 y
Et.
[ooc=-3:r]
oe
3
te dh i BSR
er
000664
ros
[ST --
RepSotrudtyNNoo.. NNWWBBRSOOL0--115455
Figure 26. Low Standard for PFOSA
J me
l pm orn e e om
emnTatedel}
J en==hi T
rar ar1meen
Ty
Emi
er ----
Tie
veils
Ean fIEe
Yimeat
A Et Fa
i
=5
_ Pe R l EEy L
Eis
B E= E
Ties 6
Ea
HE :
EERE EEE
Pages?
000665
NorthwestBioanalytical
ReSptuodryt NNoo..NNWWBBRSOOI0.-115455
Figure 27. Low Standard for M556
pe oemE--
E e Saen y m m movoaHdh
JE ne wmaon=ee3 x
PR
--
FS-- Emit ie 6
salad HE 3
:
:Z
SORA RR
er
)y
[a =me -- m 5 EEE =
_oo-- sd=4 y
mer ver moore .
--
Ee == Cli dl |
3 !
TREE R EG AR
Pages 000666
NorthwestBioanalytical
ReSptourdtyNNoo.. NNWWBBRSOOI0--115455
Figure 28. Low Standard for Ms70
Er ri p = d
reesei
ma ----Er PnmnoedEee 2
Pa E --==: yo
BE
==
i
FUL A
),
--_--
AEE RANE ey TT
E --a ] EEF
JE weSmmne e=
Tm
rn
Em
mike
oe
Fe--r
3
= EEm El
ERE
og
000667 Page 9
Northwest Bioanalyicsl
Figure 29. High Standard for PFOS.
I
Tr menrte
Earls
--_--
"et
PS
------ LG
RStudeyNNoop..NNWoWBBRSOrOI0--1t15455
E fma eC=i=s--=oly|
Hi
afaS r E
a WET r
1
= entef a=m
Cn CSnmoalEne
_
3
pp --
Tn
=
3
feea m]
CELA ELA BR
)
Page 0
oboces
NorthwestBioanalytical
RepSoturdtyNNoo.. NNWWBBRSO0I0--114555
Figure 30. High Standard for PFOA
= =" Ti ES y emm--
Ee
SE
=ternemenE t =d:
P_--I
ty =
mn
Ei
Eoac se
fo
Tn
:
:
EEE EY
)
-= I _ o= fS
v-- wRa Emaf= 2e
-- PTTim==e " ~ mn
-- Ea
::
E Ea u
AR LAN ERA EG
Paget
000669
Nose Bris
PSeivn tsisnot
Figure 31. High Standard for PFHS
-- = e - E= Teoe= e El-E= r ---- eet
E = sl h Bo E
[a=na
:
) = = An hd TERT er s Emmeer
EE 2
GEREN ENR Ser
J
rer2
000670
Nochwest Bioanalytical Figure 32. High Standard for PFOSAA RepSoturdtyNNoo..NNWWBBRSO00L--114555
[r=nes-- tre] eeaH tma eeH fd
_ mn fmo-- e= e lL y
Soman vor cee
--
EE
GTi
E mem s ] ra ae RE
Sh 5
Co
Ei of |
sled
CARE RE ESR er
)
rm al
JE I Iy
J
= i 6
ARERR RANG Ser
)
Pages
000671
Northwest Bioanalytical
RepSoturdtyNNoo..NNWWBBRSOOI0--115455
Figure 33. High Standard for PFOSA
[--] =. SE --
mlaeannee owi ondveed 13
_ ePeg s5 * y
an tr meen
en
Em
soil
Ee
:
Ve
m Got | fo 2
1
LERNER EEL Sr
)
[E S-- e m m = E mew 3
TR fooee yd=)
=:
re nm ere
----
a-- el Ei erieEl]
3
&a
ae EH
oF
AERA ERAT fey
Pages
000872
[---- Figure 34. High Standard for M556 RStuedyNNoop,.NNWoWBBRSOrOL0--1t18455
Sa E S r r s p5 2mrte d=IH5m
e S_--ree SSEEE=R y =
ET
--
--
fe dw] BI
ES
5
pias
fed
a
LAL LEL RGSAe
;
E mR = = e -
-- PR
SSEuE=le5C:2
Em mr
--
=
re
= Cie ol |
REAL BALE
)
Pages
000673
Northwest Bioanalytical Figure 35. High Standard for M570
Try HH
sn so--nm--re en
ReSptourdty NNoo..NNWWBBRSOO0I--114555
=ii = iesel |.
SeSlhpman aSaE
Sihiasa Sarea
AE RETA ey
)
5 ome y =
ar wSR S=E 3
PR
%
wre
F-- =[cu=]:n]
=
2
:
BRE EAS ha
)
Page 76
000674
